Erste Asset Management GmbH Has $9.41 Million Holdings in Ginkgo Bioworks Holdings, Inc. $DNA

Key Points

• Erste Asset Management GmbH increased its stake in Ginkgo Bioworks by 123.2%, holding approximately $9.41 million worth of shares as of the latest SEC filing.
• Various institutional investors, including Barclays PLC and Forbes J M & Co. LLP, also significantly boosted their positions in Ginkgo Bioworks, reflecting growing interest from hedge funds.
• Ginkgo Bioworks reported earnings of ($1.10) per share, surpassing expectations, with a revenue of $49.60 million for the last quarter.

Erste Asset Management GmbH increased its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 123.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,650,000 shares of the company's stock after purchasing an additional 910,668 shares during the quarter. Erste Asset Management GmbH owned about 2.84% of Ginkgo Bioworks worth $9,405,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of DNA. US Bancorp DE lifted its holdings in Ginkgo Bioworks by 43.5% in the first quarter. US Bancorp DE now owns 6,302 shares of the company's stock worth $36,000 after purchasing an additional 1,911 shares during the period. CWM LLC lifted its holdings in Ginkgo Bioworks by 667.6% in the 1st quarter. CWM LLC now owns 12,274 shares of the company's stock valued at $70,000 after acquiring an additional 10,675 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Ginkgo Bioworks in the 1st quarter valued at about $76,000. Green Alpha Advisors LLC lifted its holdings in Ginkgo Bioworks by 31.7% in the 1st quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after acquiring an additional 4,449 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Ginkgo Bioworks in the 4th quarter valued at about $116,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Price Performance

NYSE DNA traded down $0.4970 on Monday, hitting $12.0530. 926,471 shares of the company were exchanged, compared to its average volume of 1,528,118. The company's 50 day moving average price is $11.55 and its 200-day moving average price is $9.34. The firm has a market capitalization of $713.54 million, a P/E ratio of -2.05 and a beta of 1.50. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $16.85.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.44) by $0.34. The firm had revenue of $49.60 million for the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks had a negative return on equity of 43.25% and a negative net margin of 136.56%. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current year.

Analyst Upgrades and Downgrades

DNA has been the subject of a number of research analyst reports. Cowen reissued a "buy" rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. BTIG Research upped their price target on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $9.50.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.